Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study

T.A.C. de Vries*, M.E.W. Hemels, F. Cools, H.J.G.M. Crijns, L. Yperzeele, P. Vanacker, I. Blankoff, P. Lancellotti, G.H. Mairesse, A. de Veer, R.C. Arroyo, E. Catez, M. de Pauw, T. Vanassche, C. de Asmundis, P. Kirchhof, R. De Caterina, J.R. de Groot, P.r.i.n.c.i.p.a.l. ETNA-AF-Europe, ETNA-AF-Europe principal investigators from Belgium and the Netherlands

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.

Methods With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 ml/min, weight

Results Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.

Conclusion There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.

Original languageEnglish
Pages (from-to)158-167
Number of pages10
JournalNetherlands Heart Journal
Volume29
Issue number3
DOIs
Publication statusPublished - 1 Mar 2021

Keywords

  • anticoagulants
  • clinical trial
  • haemorrhage
  • k oral anticoagulants
  • management
  • off-label use
  • phase iv
  • routine clinical-practice
  • stroke
  • thromboembolism
  • trends
  • warfarin
  • Anticoagulants
  • Stroke
  • MANAGEMENT
  • phase IV
  • TRENDS
  • ROUTINE CLINICAL-PRACTICE
  • Off-label use
  • WARFARIN
  • Clinical trial
  • Haemorrhage
  • Thromboembolism
  • K ORAL ANTICOAGULANTS

Cite this